Olezarsen for Managing Severe Hypertriglyceridemia and Pancreatitis Risk
Among patients with severe hypertriglyceridemia, treatment with olezarsen led to a significantly greater reduction in the triglyceride level at 6 months and in the incidence of acute pancreatitis than placebo. (Funded by Ionis Pharmaceuticals; CORE-TIMI 72a and CORE2-TIMI 72b ClinicalTrials.gov numbers, NCT05079919 and NCT05552326.).
Authors
- Lina Badimón (ORCID: https://orcid.org/0000-0002-9162-2459)
- Thomas A Prohaska (ORCID: https://orcid.org/0000-0002-1406-692X)
- Róbert Gábor Kiss (ORCID: https://orcid.org/0000-0003-0514-7530)
- Elaine Waldman
- Erica L. Goodrich (ORCID: https://orcid.org/0000-0002-8541-264X)
- Marc S. Sabatine (ORCID: https://orcid.org/0000-0002-0691-3359)
- Shuting Xia (ORCID: https://orcid.org/0000-0003-2577-4339)
- Robert P. Giugliano (ORCID: https://orcid.org/0000-0003-4110-7675)
- Maciej Banach (ORCID: https://orcid.org/0000-0001-6690-6874)
- Anne C. Goldberg (ORCID: https://orcid.org/0000-0002-8876-099X)
- Philippe Moulin (ORCID: https://orcid.org/0000-0002-9585-0571)
- Stephen James Nicholls (ORCID: https://orcid.org/0000-0002-9668-4368)
- Min‐Ji Charng (ORCID: https://orcid.org/0000-0002-0949-9026)
- Brian A. Bergmark (ORCID: https://orcid.org/0000-0003-4360-7606)
- Filipe A. Moura (ORCID: https://orcid.org/0000-0001-8017-1675)
- S. M. Zhang
- Dirk Blom (ORCID: https://orcid.org/0000-0003-3965-5912)
- Børge Grønne Nordestgaard (ORCID: https://orcid.org/0000-0002-1954-7220)
- Veronica J. Alexander (ORCID: https://orcid.org/0000-0003-3729-5749)
- Erik S.G. Stroes (ORCID: https://orcid.org/0000-0001-9555-6260)
- André Zimerman (ORCID: https://orcid.org/0000-0001-8977-6929)
- Sabina A. Murphy (ORCID: https://orcid.org/0000-0002-8231-3611)
- Michal Vráblík (ORCID: https://orcid.org/0000-0002-7226-1926)
- Daniel Gaudet (ORCID: https://orcid.org/0000-0002-5185-3666)
- Sotirios Tsimikas (ORCID: https://orcid.org/0000-0001-9834-9494)
- Nicholas Marston (ORCID: https://orcid.org/0000-0001-6164-4617)
- Julia Weinland
- Dan Li (ORCID: https://orcid.org/0000-0002-1264-5952)
- Yu Mi Kang (ORCID: https://orcid.org/0000-0002-6272-0666)
- Hofit Cohen
- Assen Goudev
Institutions
- Semmelweis University (HU)
- Université du Québec à Chicoutimi (CA)
- Universitat de Vic - Universitat Central de Catalunya (ES)
- Brigham and Women's Hospital (US)
- Foundation for Biomedical Research (US)
- Harvard University (US)
- University of Cape Town (ZA)
- Washington University in St. Louis (US)
- Charles University (CZ)
- Sheba Medical Center (IL)
- Ionis Pharmaceuticals (United States) (US)
- Military Hospital (PK)
- Instituto de Salud Carlos III (ES)
- Queen Giovanna Hospital (BG)
- Copenhagen University Hospital (DK)
- Amsterdam UMC Location University of Amsterdam (NL)
- Yale University (US)
- University of California San Diego (US)
- Hospital Moinhos de Vento (BR)
- VA Connecticut Healthcare System (US)
- Central Military Hospital (NL)
- Hôpital Lyon Sud (FR)
- Monash Health (AU)
- Medical University of Lodz (PL)
- Fundació Catalana per a la Recerca i la Innovació (ES)
- Thrombolysis in Myocardial Infarction Study Group (US)
- Monash Institute of Medical Research (AU)
- Université de Montréal (CA)
Publication Details
- Journal
- New England Journal of Medicine
- Published
- 2025-11-08
- DOI
- https://doi.org/10.1056/nejmoa2512761
- Citations
- 20
- Primary Topic
- Pancreatitis Pathology and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 40.13